Information contained on this page is provided by an independent third-party content provider. WorldNow and this Station make no warranties or representations in connection therewith. If you have any questions or comments about this page please contact firstname.lastname@example.org.
SOURCE Dyadic International, Inc.
JUPITER, Fla., July 9, 2014 /PRNewswire/ -- Dyadic International, Inc. ("Dyadic") (OTCQX: DYAI), a global biotechnology company focused on the discovery, development, manufacture and sale of enzymes and other proteins for the bioenergy, bio-based chemicals, biopharmaceutical, food and feed industries, announced today details regarding its new Bakenzyme project. In collaboration with several industry partners, the Bakenzyme project seeks to develop a novel, pure and widely applicable xylanase-oxidase enzyme product for the baking industry.
Dyadic's Chief Operating Officer, Danai Brooks, stated, "The aim of this project is to create an enzyme product that improves the structure of bread and increases the bioavailability of health components naturally present in flour. Baking enzymes are a large and growing market. We expect the global baking enzyme market to approach $700 million in five years and believe there is a distinct need for dedicated enzyme mixtures without the negative side activities of products currently available to bakeries."
Enzymes are widely used today by industrial bakeries to increase the stability and rising power of dough, improve crumb structure, increase volume and prevent staling. International bans on the widely popular and highly effective chemical oxidizing agent potassium bromate created the need for safe, yet effective, alternatives. However, most existing enzyme products, such as the currently used glucose oxidase (GOX), are less effective and contain side activities, which can negatively impact bread quality.
Dr. Sandra Hinz, Dyadic's Head of New Product Development, stated, "The novel enzyme mixtures we are developing within the Bakenzyme project will allow manufacturers to combine the benefits of multiple enzymes, improve overall performance and eliminate unwanted side effects without the need for additional additives. As a result consumers can expect consistently higher quality bread with improved texture and more sustainable ingredients. Dyadic's participation in this important program highlights the capabilities of our C1 Expression System to develop innovative products. Participation in the Bakenzyme project and other private-public programs helps us advance our technology platform and increase the breadth of our enzyme library, which may have applications in a wide variety of industries."
Dyadic International, Inc. is a global biotechnology company that uses its patented and proprietary technologies to conduct research, development and commercial activities for the discovery, development, manufacture and sale of enzymes and other proteins for the bioenergy, bio-based chemical, biopharmaceutical and industrial enzyme industries. Dyadic utilizes an integrated technology platform based on its patented and proprietary C1 microorganism, which enables the development and large scale manufacture of low cost enzymes and other proteins for diverse market opportunities. The C1 platform technology can also be used to screen for the discovery of novel genes. In addition to the sale of proprietary enzyme products, Dyadic actively pursues licensing arrangements and other commercial opportunities to leverage the value of these technologies by providing its partners and collaborators with the benefits of manufacturing and/or utilizing the enzymes and other proteins which these technologies help produce. For further information, please visit Dyadic's website at www.dyadic.com. Dyadic trades on the OTCQX tier of the OTC marketplace. Investors can find real-time quotes, market information and financial reports for Dyadic on the OTC marketplace website at www.otcmarkets.com/stock/DYAI/quote.
Cautionary Note Regarding for Forward-Looking Statements
Certain statements contained in this press release are forward-looking statements within the meaning of the federal securities laws. Statements about our beliefs and expectations regarding our technology platform, research efforts, the need for dedicated enzyme mixtures, consumer experience and our successful production of enzymes with minimal negative side activities may constitute forward-looking statements. These forward-looking statements involve risks and uncertainties that could cause Dyadic's actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by such forward-looking statements. Investors are urged to consider these factors carefully in evaluating the forward-looking statements and are cautioned not to place undue reliance on such forward-looking statements. Any forward-looking statements speak only as of the date of this press release and, except as required by law, Dyadic expressly disclaims any intent or obligation to update any forward-looking statements to reflect actual results, any changes in expectations or any change in events.
©2012 PR Newswire. All Rights Reserved.